What Is Sematrinity? India's New GLP-1 Breakthrough Explained
Sematrinity is Sun Pharma's generic semaglutide injection for type 2 diabetes and weight loss in India. Learn how it works, launch details post-patent expiry, and what to expect.
Something historic happened in India's pharmaceutical market today. On March 20, 2026, the patent on semaglutide - the active ingredient in Ozempic and Wegovy - expired. Overnight, over 50 Indian generic manufacturers gained the legal right to manufacture and sell their own versions.
The most significant launch is Sun Pharma's Sematrinity - a once-weekly generic semaglutide injection that brings GLP-1 therapy within reach of many more patients across India.
What is Sematrinity?
Sematrinity is a generic semaglutide injection developed by Sun Pharma, India's largest pharmaceutical company. It is a GLP-1 receptor agonist - the same class of medication as Ozempic and Wegovy - containing the identical active molecule at the same concentrations, delivered via a prefilled pen.
Key details:
- Active ingredient: Semaglutide
- Form: Once-weekly subcutaneous injection (prefilled pen)
- Doses: 0.25 mg to 2.4 mg
- Primary indication: Type 2 diabetes management (adjunct to diet and exercise)
- Approval: DCGI-approved, December 2025
- Manufacturer: Sun Pharmaceutical Industries Ltd.
Sun Pharma has also launched Noveltreat as a separate brand focused specifically on chronic weight management in obesity patients - keeping the two indications distinct.
How does Sematrinity work?
Sematrinity works exactly like branded semaglutide. It mimics the GLP-1 (glucagon-like peptide-1) hormone that your gut naturally releases after eating. This triggers several effects:
- Stimulates insulin release from the pancreas (in a glucose-dependent manner)
- Suppresses glucagon - reducing excess glucose production by the liver
- Slows gastric emptying - food stays in the stomach longer, extending satiety
- Reduces appetite signals in the brain
Together, these mechanisms improve blood sugar control for people with type 2 diabetes and produce meaningful weight loss as a secondary benefit.
What does the clinical evidence say?
Semaglutide's clinical evidence base is among the strongest in modern medicine. The SUSTAIN trial program (for diabetes) and STEP trial program (for obesity) together involved tens of thousands of patients across multiple countries.
Key results from semaglutide trials:
- HbA1c reduction: Average 1.5–2% drop - superior to most oral diabetes medications
- Weight loss: Average 10–15% body weight reduction over 68 weeks
- Long-term maintenance: Results sustained up to 4 years in extension studies
- Cardiovascular benefit: Reduced risk of major cardiovascular events in patients with established heart disease
Sun Pharma conducted India-specific Phase III studies supporting DCGI approval, demonstrating safety and efficacy in Indian adult populations across cities including Lucknow and Delhi.
Launch details: what is available from today
As of March 20, 2026, Sematrinity is available:
- Pharmacies: Major chains nationwide and platforms including 1mg
- Hospitals and clinics: Endocrinology and diabetology departments in metro cities
- Prescription required: Available only with a valid prescription from a registered medical practitioner
Availability in metro cities (Mumbai, Delhi, Bengaluru, Hyderabad, Chennai) from launch day. Wider national rollout, including tier-2 cities and rural areas, is expected within weeks through Sun Pharma's established distribution network.
What does Sematrinity cost?
This is where the patent expiry makes a real difference.
| Option | Monthly cost (approx.) |
|---|---|
| Imported Ozempic | ₹10,000–₹18,000 |
| Sematrinity (Sun Pharma) | ₹4,000–₹8,000 |
| Other generics (Zydus, Dr. Reddy's, etc.) | ₹3,500–₹7,000 |
The approximately 50% reduction compared to imported semaglutide brings GLP-1 therapy into reach for a significantly larger segment of India's diabetic and obese population.
With India carrying a diabetes burden of approximately 77 million cases - the second largest in the world - and urban obesity rates hitting 20% in major cities, the arrival of affordable generic semaglutide could meaningfully shift treatment patterns.
Sematrinity vs other generics launching today
Sematrinity is not the only semaglutide generic launching with the patent expiry. Major players include:
- Semaglyn - Zydus Lifesciences
- Dr. Reddy's generic semaglutide
- Cipla, Lupin, and approximately 50+ others
Sun Pharma's advantage is brand recognition, distribution scale, and manufacturing quality consistency. For patients choosing between generics, the prescribing physician's recommendation and pharmacy availability will typically guide the decision.
How to use Sematrinity
Sematrinity is self-administered via a prefilled pen injected subcutaneously (under the skin) once weekly, into the abdomen, thigh, or upper arm.
Standard titration:
- Weeks 1–4: 0.25 mg once weekly
- From week 5: 0.5 mg (or as prescribed)
- Maximum dose: 1 mg for diabetes; 2.4 mg for weight management (via Noveltreat)
Start with a consultation with an endocrinologist or diabetologist to confirm appropriate dosing for your situation.
Tips for best results
- Combine with a 1,500 calorie diet (or as advised by your dietitian) and 150 minutes of physical activity per week
- Source only from licensed pharmacies - counterfeit GLP-1 products are a known risk in India and internationally
- Expect nausea in the first few weeks - this is common and typically fades
- Log your doses and symptoms consistently; it helps you and your doctor spot patterns early
WeightEasy supports semaglutide tracking including generics, and will be updated to include Sematrinity as Indian users adopt it.
Final takeaway
Sematrinity is Sun Pharma's generic semaglutide, launching in India on March 20, 2026 - the same day as semaglutide's patent expiry. Priced at roughly half the cost of imported Ozempic, it brings once-weekly GLP-1 therapy within realistic reach for a much larger number of Indian patients with type 2 diabetes and obesity.
Always consult your healthcare provider before starting any medication.
Sources
- Sun Pharmaceutical Industries Ltd. - Sematrinity product launch communications, March 2026
- DCGI approval: December 2025
- SUSTAIN trial program: Semaglutide in type 2 diabetes (multiple NEJM publications, 2018–2022)
- STEP trial program: Semaglutide for obesity (Wilding JPH et al., NEJM, 2021)
- Ozempic and Wegovy prescribing information - Novo Nordisk
FAQ
When does Sematrinity launch in India?
Sematrinity launched in India on March 20, 2026, following the expiry of the semaglutide patent on that date.
Is Sematrinity for weight loss?
Sematrinity is primarily approved for type 2 diabetes management in India. Sun Pharma's sister brand Noveltreat is positioned specifically for chronic weight management in obesity patients.
What are Sematrinity's side effects?
The most common side effect is nausea, which is typical for all semaglutide products. It generally fades within the first few weeks of treatment. Other GI effects including diarrhea, vomiting, and constipation can also occur, consistent with the semaglutide class.
Where can I buy Sematrinity in India?
Sematrinity is available through major pharmacy chains and clinics nationwide, including platforms like 1mg. Availability began in metros from launch day, with wider rollout across India expected soon.
How much does Sematrinity cost in India?
Sematrinity is priced at approximately ₹4,000–₹8,000 per month - roughly 50% below the cost of imported Ozempic, making it significantly more accessible for Indian patients.